From professional translators, enterprises, web pages and freely available translation repositories.
lymphatic system disorders immune system disorders endocrine disorders
klassifika tal - organi mard tad- demm u tas- sistema limfatika mard marbut mal- metabolismu u nutrizzjoni mard fis- sistema endokrinarja mard marbut mal- metabolismu u nutrizzjoni
the substances that act naturally on the endocrine system are numerous and are everyday products, such as rice, soya, coffee and paracetamol.
is-sustanzi li jaġixxu b'mod naturali fuq is-sistema endokrinali huma differenti u huma prodotti li jiġu kkunsmati ta' kuljum, bħar-ross, is-soja, il-paracetamol, eċċ.
in this instance, the most dangerous period is when the endocrine system is developing (prenatal life, early childhood and puberty).
għall-argument, il-perjodu l-aktar perikoluż huwa dak meta s-sistema endokrinali tkun qed tiżviluppa (il-ħajja qabel it-twelid, it-tfulija u l-pubertà).
they can cause impairment of the immune system, the nervous system, the endocrine system and the reproductive functions and are also suspected of causing cancer.
jistgħu jikkawżaw dannu fis-sistema immunitarja, fis-sistema nervuża, fis-sistema endokrinu u fil-funzjonijiet riproduttivi u hemm anke suspett li jikkawżaw il-kanċer.
these pollutants cause impairment of the immune system, the nervous system, the endocrine system and the reproductive functions and are also suspected of causing cancer.
jistgħu jikkawżaw indeboliment fis-sistema immunitarja, fis-sistema nervuża, fis-sistema endokrinali u fil-funzjonijiet riproduttivi u hemm anke suspett li jikkawżaw il-kanċer.
1.10 the eesc recommends that the european commission draw up, after consulting endocrinologists, a list of products that may have a negative impact on the development of the endocrine system.
1.10 il-kese jirrakkomanda li l-kummissjoni ewropea, wara li ssir konsultazzjoni tal-komunità tal-endokrinologi, tidentifika lista ta' prodotti li jista' jkollhom impatt negattiv fuq l-iżvilupp tas-sistema endokrinali.
the concept of endocrine disrupters is not new, and the active substances used in crop protection or biocides in the eu are subjected to a series of tests that include trials for the effect on the endocrine system.
il-kunċett ta' interferent endokrinali mhuwiex ġdid u s-sustanzi attivi użati fil-protezzjoni tal-uċuħ tar-raba' jew fil-bijoċidi fl-ue jgħaddu minn għadd ta' testijiet li jinkludu provi ta' effett fuq is-sistema endokrinali.
carcinoid tumour (a tumour of the endocrine system that produces hormones); malignant melanoma (a type of skin cancer affecting cells called melanocytes).
tumur karċinojdu (tumur tas-sistema endokrinali li tipproduċi l-ormoni); melanoma malinja (tip ta’ kanċer tal-ġilda li jaffettwa ċ-ċelloli msejħa melanocytes).
the publication by the efsa of the appointments to the scientific panel has not provided any reassurance, as it emerges, for example, that only 3 of the 18 members had any scientific experience in the field of the endocrine system.
il-pubblikazzjoni mill-efsa tal-membri tal-bord xjentifiku maħtura għal dan il-għan ma tantx tat assigurazzjoni, għax pereżempju din uriet li 3 biss mit-18-il membru kellhom xi esperenza xjentifika fil-qasam tas-sistema endokrinali.
new and emerging scientific findings-such as the potential of certain chemicals, among them pesticides, to disrupt the functioning of the endocrine system even at low concentrations-underline the possible risks for humans and the environment from the use of such substances.
sejbiet xjentifiċi ġodda u emerġenti bħall-potenzjal ta’ ċerti kimiċi, fosthom il-pestiċidi, li jfixklu t-tħaddim tas-sistema endokrinali anki f’konċentrazzjonijiet baxxi – jenfasizzaw ir-riskji possibbli għall-bnedmin u għall-ambjent mill-użu ta’ sustanzi bħal dawn.
patients with signs or symptoms compatible with autoimmune disorders should be evaluated carefully, and the benefit-risk of continued interferon therapy should be reassessed (see also endocrine system in sections 4.4 and 4.8).
61 b’ sintomi kompatibbli ma ’ mard awtoimmuni għandhom jiġu evalwati bir- reqqa, u r- riskju- benefiċju li titkompla terapija b’ interferon għandu jerġa ’ jiġi evalwat (ara wkoll sistema endokrinarja f’ sezzjonijiet 4. 4 u 4. 8).
